Literature DB >> 9797481

Human osteoclast formation and activity in vitro: effects of alendronate.

V Breuil1, F Cosman, L Stein, W Horbert, J Nieves, V Shen, R Lindsay, D W Dempster.   

Abstract

Recent advances in technique have made it possible to study human osteoclast (OC) formation and activity in vitro. The object of the present study was to determine the effects of alendronate (ALN) on human OCs generated from precursors obtained from standard peripheral blood samples. Peripheral blood mononuclear cells from 14 postmenopausal women were cocultured with ST2 stromal cells on bone slices in the presence of 10(-7) M 1,25-dihydroxyvitamin D3, 10(-8) M dexamethasone, and 25 ng/ml human macrophage colony-stimulating factor. After 21 days, the cultures contained numerous OCs, which were characterized by multinuclearity, the presence of tartrate-resistant acid phosphatase, calcitonin and vitronectin receptors, and the ability to resorb substantial amounts of bone, which was inhibited by calcitonin. The percentage area of bone resorbed per slice was highly correlated (r = 0.89, p < 0.001) with the concentration of Type I collagen cross-linked C-telopeptides (CTx) released into the culture medium. When added to the medium, ALN inhibited bone resorption at concentrations < or =10(-7) M. At 10(-7) M, inhibition was achieved primarily by a reduction in OC activity without a marked effect on OC number. At the highest concentration studied (10(-5) M), both OC number and resorption were profoundly decreased. Overnight preincubation of bone slices in ALN, without further exposure to ALN, resulted in an inhibition of resorption that was similar to that seen when ALN was present in the medium throughout the entire culture period. We conclude that, except at very high concentrations, the predominant mechanism of action of ALN is to inhibit the activity of differentiated human OCs with little or no effect on recruitment. Interaction between the OC and ALN on the bone surface is an important component of the inhibitory mechanism. Measurement of CTx in tissue culture medium is a convenient method for assessment of bone resorption in human OC cultures and offers a number of advantages over morphometric analysis of the bone slice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797481     DOI: 10.1359/jbmr.1998.13.11.1721

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  23 in total

1.  A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration.

Authors:  Y Ohbayashi; A Iwasaki; F Nakai; T Mashiba; M Miyake
Journal:  Osteoporos Int       Date:  2019-11-25       Impact factor: 4.507

Review 2.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Low concentrations of zoledronic acid are better at regulating bone formation and repair.

Authors:  Xiaomeng Yang; Yanqin Lu; Zhiliang Li; Yanzhou Wang; Fei Zhao; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2013-02

4.  The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration.

Authors:  Yumiko Ohbayashi; Fumi Nakai; Akinori Iwasaki; Takaaki Ogawa; Yuka Yamamoto; Yoshihiro Nishiyama; Minoru Miyake
Journal:  Odontology       Date:  2016-10-21       Impact factor: 2.634

5.  ATRAID regulates the action of nitrogen-containing bisphosphonates on bone.

Authors:  Lauren E Surface; Damon T Burrow; Jinmei Li; Jiwoong Park; Sandeep Kumar; Cheng Lyu; Niki Song; Zhou Yu; Abbhirami Rajagopal; Yangjin Bae; Brendan H Lee; Steven Mumm; Charles C Gu; Jonathan C Baker; Mahshid Mohseni; Melissa Sum; Margaret Huskey; Shenghui Duan; Vinieth N Bijanki; Roberto Civitelli; Michael J Gardner; Chris M McAndrew; William M Ricci; Christina A Gurnett; Kathryn Diemer; Fei Wan; Christina L Costantino; Kristen M Shannon; Noopur Raje; Thomas B Dodson; Daniel A Haber; Jan E Carette; Malini Varadarajan; Thijn R Brummelkamp; Kivanc Birsoy; David M Sabatini; Gabe Haller; Timothy R Peterson
Journal:  Sci Transl Med       Date:  2020-05-20       Impact factor: 17.956

6.  Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.

Authors:  Luigi Sinigaglia; Massimo Varenna; Silvia Casari
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

7.  Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.

Authors:  Masanobu Ohishi; Riccardo Chiusaroli; Michael Ominsky; Frank Asuncion; Clare Thomas; Richa Khatri; Paul Kostenuik; Ernestina Schipani
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

8.  Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.

Authors:  Samuel Gourion-Arsiquaud; Matthew R Allen; David B Burr; Deepak Vashishth; Simon Y Tang; Adele L Boskey
Journal:  Bone       Date:  2009-11-17       Impact factor: 4.398

9.  Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.

Authors:  Kyle G Halvorson; Molly A Sevcik; Joseph R Ghilardi; Lucy J Sullivan; Nathan J Koewler; Frieder Bauss; Patrick W Mantyh
Journal:  J Pain Symptom Manage       Date:  2008-04-14       Impact factor: 3.612

10.  Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.

Authors:  Robyn K Fuchs; Roger J Phipps; David B Burr
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.